Sadeghi Saeed, Bejjani Anthony, Finn Richard S
UCLA Oncology, 2020 Santa Monica Blvd, Suite 230, Santa Monica, CA 90404, USA.
UCLA Oncology, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA 90404, USA.
Surg Oncol Clin N Am. 2019 Oct;28(4):695-715. doi: 10.1016/j.soc.2019.06.015.
In the past decade, there has been significant progress in the treatment of primary liver cancer. There has been increasing knowledge of the molecular alterations occurring in these tumors, which is now being translated into patient care. Ongoing clinical trials will further advance the therapeutic options available to patients, including the introduction of molecular targeted therapeutics and immunotherapy approaches. Critical to the success of these new drugs, is the appropriate use of them in the clinic to maximize efficacy and limit toxicity.
在过去十年中,原发性肝癌的治疗取得了显著进展。人们对这些肿瘤中发生的分子改变有了越来越多的了解,这些知识现在正被应用于患者护理中。正在进行的临床试验将进一步推进患者可获得的治疗选择,包括引入分子靶向治疗和免疫治疗方法。这些新药成功的关键在于在临床中合理使用它们,以最大限度地提高疗效并限制毒性。